About vedolizuma b
Gut-selective integrin antagonist
Used for
- Moderate to severe ulcerative colitis in adults
- Moderate to severe Crohn’s disease in adults
Usual adult dose
Maintenance: 108 mg under the skin every two weeks, usually after initial intravenous treatment.
Common side effects
- Injection-site reactions
- Headache
- Joint pain
- Nasopharyngitis or other infections
Important warnings
- Serious infections can occur; assess for infection before treatment.
- Do not use during an active serious infection.
- Rarely, progressive multifocal leukoencephalopathy (PML), a serious brain infection, has been reported.
- Vaccinations should be reviewed; avoid live vaccines during treatment.
Pregnancy
Human pregnancy data are limited. Use only when the expected benefit outweighs potential risk.
Breastfeeding
Vedolizumab passes into breast milk in small amounts; effects on the infant are uncertain.
Interactions
- Avoid concurrent natalizumab or other biologic immunosuppressants because infection risk may increase.
- Avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.